Andere talen Indaptus Therapeutics, Inc.

Aandelen

INDP

US45339J1051

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,11 ^USD	-3,21%		-10,59%	+19,89%

14/03	Top stijgers op de premarket	MT
13/03	Indaptus Therapeutics, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting	11/04
Indaptus Therapeutics : April 2024 April 2024 Investor Presentation	08/04
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference	28/03
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting	25/03
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024	18/03
Top Premarket Gainers	14/03
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	13/03
Top Midday Gainers	04/03
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort	04/03
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial	04/03
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference	15/02
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels	08/02
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels	08/02
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology	04/01
Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/11
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	06/11
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study	06/11
Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20	06/11
Indaptus Therapeutics, Inc. Releases Interim Data from the First Cohort of Four Patients in its Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20	31-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Indaptus Therapeutics, Inc.

Aandelen

INDP

US45339J1051

Andere talen

Filters